Project Grant R01CA286147
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$1.1M
Federal Agency
National Cancer Institute
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
The National Cancer Institute awarded a $627,474 Project Grant under its Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Dana-Farber Cancer Institute in Boston, Massachusetts. The grant will fund a 5-year research project titled "Mapping the Epigenetic Dynamics of Prostate Cancer Progression: Integrating Liquid Biopsies and Single-Cell Epigenomics for Early Detection of Lineage Plasticity and Clinical Decision-Making." The project aims to utilize innovative...
This federal Project Grant award, valued at $415,902 and issued by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research aimed at overcoming therapy resistance and lineage plasticity in castration-resistant prostate cancer. The award to the University of Massachusetts Boston will fund investigations into how the transcription factor FOXA2, in collaboration with AP-1, drives prostate cancer cells into an adaptive multilineage...
The National Cancer Institute (NCI) awarded a five-year, $2,452,400 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the Dana-Farber Cancer Institute, Inc. in Boston, Massachusetts. The grant supports the program "Convergent Epigenetic Control of Diverse Neuroendocrine Cancers," which aims to study the epigenetic and transcriptional states required for the development of neuroendocrine cancers across four tissue types: small intestinal neuroendocrine tumors,...
The federal Project Grant award R01CA279528 of $497,109 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) is funding a 5-year research project at Washington State University to elucidate the role of tryptophan hydroxylase 1 (TPH1) in neuroendocrine prostate cancer (NEPC).
The key objectives are to delineate the molecular mechanisms by which TPH1 activates the mTOR-FOXM1/TAZ/E2F1 signaling axis to drive NEPC growth and neuroendocrine differentiation, as well as...
This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research focused on overcoming mechanisms of PTPN1 driving therapy- and castration-resistant prostate cancer with novel theranostics. The $472,458 grant, awarded to the University of Texas Southwestern Medical Center in Dallas, TX, aims to examine the regulation of the PTPN1 gene and its role in the transdifferentiation of prostate cancer cells,...
This $371,719 Project Grant awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) aims to characterize epigenetic targets, specifically the histone methyltransferase NSD2, and their role in driving the oncogenic androgen receptor (AR) transcriptional program in prostate cancer. The research, to be conducted by the University of Pennsylvania, has two main objectives:
Gain deeper molecular insights into how NSD2 influences the chromatin landscape to...
This $392,410 National Cancer Institute (NCI) Project Grant award, issued under the Cancer Research Manpower program (CFDA 93.398), supports research at Weill Medical College of Cornell University to investigate the drivers of tumor heterogeneity and the progression to neuroendocrine prostate cancer (NEPC). The 3-year project will use novel genetically-engineered mouse models and organoid-based platforms to study the role of a previously undescribed tumor subpopulation in the transition from...
This $720,416 Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Sloan-Kettering Institute for Cancer Research aims to develop a novel theranostic (therapeutic and diagnostic) approach for treating prostate cancer, specifically targeting neuroendocrine prostate cancer (NEPC).
The key products and services to be delivered under this 5-year award include:
Evaluating the therapeutic efficacy of DLL3-specific CAR-T cells in NEPC...
The National Cancer Institute (NCI) awarded a $549,357 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Washington University to conduct research on the regulation of the androgen receptor (AR) by the long non-coding RNA NXTAR in prostate cancer. The research aims to determine the mechanism of NXTAR suppression in castration-resistant prostate cancers, synthesize PSMA-targeted nanoparticles with NXTAR-N5 oligonucleotides and AR pathway inhibitors, and evaluate these...
This R01 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $1,969,645 to Duke University to conduct research on alternative polyadenylation (APA) regulation and its role in prostate cancer progression. The project aims to:
Identify APA target genes involved in the transition from androgen-dependent to castration-resistant prostate cancer using multi-omics analyses of clinical samples and cell models.
Develop a computational...